妊娠前甲状腺替代治疗女性的甲状腺实验室检测与管理及妊娠结局
加拿大阿尔伯塔省回顾性队列研究纳入妊娠前两年内使用甲状腺替代治疗的10680例分娩,82.2%孕期至少检测一次TSH(中位孕6周),43.7%调整左甲状腺素剂量。孕期TSH<0.10 mIU/L与早产风险升高相关(aOR 2.14,95%CI 1.51-2.78),TSH≥10.00 mIU/L未与不良结局相关。
要点
- 妊娠前使用甲状腺替代治疗者中17.8%孕期未检测TSH。
- 孕期TSH<0.10 mIU/L与早产风险升高相关(aOR 2.14)。
- 应避免孕期左甲状腺素过度治疗。
核心结论
- 多数妊娠前使用甲状腺替代治疗的女性孕期检测了TSH,但17.8%未检测。
- 孕期左甲状腺素过度治疗(TSH<0.10 mIU/L)与早产相关。
- 临床应谨慎避免孕期左甲状腺素过度治疗。
研究设计与样本
- 加拿大阿尔伯塔省回顾性队列研究,纳入妊娠前两年内使用甲状腺替代治疗且于2014年10月至2017年9月分娩的女性。
- 共纳入10680例分娩,链接分娩记录、医生账单、实验室和药房行政数据。
主要发现
- 8774例(82.2%)孕期至少检测一次TSH,中位孕6周。
- 4321例(43.7%)孕期调整左甲状腺素剂量。
- 孕期TSH<0.10 mIU/L与早产风险升高相关(校正OR 2.14,95%CI 1.51-2.78)。
- 孕期TSH≥10.00 mIU/L在多变量分析中未与任何不良妊娠或新生儿结局相关。
关键数值与推荐
- 过度治疗定义为孕期TSH<0.10 mIU/L,对照为TSH 0.10-4.00 mIU/L。
- 治疗不足定义为孕期TSH≥10.00 mIU/L。
临床怎么用
- 妊娠前使用甲状腺替代治疗的女性应监测孕期TSH。
- 避免左甲状腺素过度治疗以致TSH<0.10 mIU/L,以降低早产风险。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Background: Women with hypothyroidism before pregnancy often require an increase in their levothyroxine dosage to maintain a euthyroid state during pregnancy. The objectives of this study were to investigate: (i) the frequency and distribution of thyrotropin (TSH) testing and levothyroxine dosage adjustment by gestational age, (ii) the magnitude of levothyroxine increase by the underlying etiology of hypothyroidism, and (iii) the relationship of overtreatment or undertreatment during pregnancy with adverse pregnancy outcomes among women using thyroid replacement before pregnancy. Methods: A retrospective cohort study of pregnancies in women on thyroid replacement before pregnancy in Alberta, Canada, was performed. Women using thyroid replacement anytime during the two years before pregnancy who delivered between October 2014 and September 2017 were included. Delivery records, physician billing, and laboratory and pharmacy administrative data were linked. Outcomes included characteristics of TSH testing, levothyroxine dosing, and pregnancy outcomes. The frequency and gestational timing of TSH testing and levothyroxine adjustments were calculated. Multiple logistic regression was used to test whether pregnancies with TSH <0.10 mIU/L (overtreatment) or TSH ≥10.00 mIU/L (undertreatment) compared with control pregnancies (TSH 0.10-4.00 mIU/L) were associated with adverse pregnancy and neonatal outcomes. Results: Of the 10,680 deliveries, 8774 (82.2%) underwent TSH testing at least once during pregnancy, at a median gestational age of six weeks. An adjustment of levothyroxine dosage was made for 4321 (43.7%) during pregnancy. TSH in pregnancy below 0.10 mIU/L increased the odds of preterm delivery when compared with control pregnancies (adjusted odds ratio, 2.14 [95% confidence interval 1.51-2.78]). TSH ≥10.00 mIU/L during pregnancy was not associated with any adverse pregnancy or neonatal outcomes in the multivariable analysis. Conclusions: Although most women on thyroid replacement before conception had TSH measured at some point during pregnancy, it is concerning that 17.8% did not. Levothyroxine overtreatment in pregnancy was associated with preterm delivery. These findings suggest that clinicians should be careful to avoid overtreatment with levothyroxine in pregnancy.
引用
- Lemieux P, Yamamoto JM, Nerenberg KA, et al. Thyroid Laboratory Testing and Management in Women on Thyroid Replacement Before Pregnancy and Associated Pregnancy Outcomes. Thyroid. 2020. PMID: 33108964. doi:10.1089/thy.2020.0609
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。